FDA approves Progenics' drug for rare tumors

The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news

Related Links:

menez-Roqueplo AP Abstract PURPOSE: Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors. While most PPGL are benign, up to 20% may become metastatic with SDHB- and FH-mutated tumors showing the higher risk. We aimed at determining the contribution of immortalization mechanisms to metastatic progression. EXPERIMENTAL DESIGN: Immortalization mechanisms were investigated in 200 tumors. To identify telomerase (+) tumors we analyzed genomic alterations leading to transcriptional activation of TERT comprising promoter mutations, hypermethylation and gain copy number. To identify tumors that a...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are the most heritable endocrine tumors. Genetic testing for 12 driver susceptibility genes is recommended in all PCC and PGL cases. However, detection of som...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
The Food and Drug Administration on Tuesday approved the first ever non-surgical treatment for the rare neuroendocrine cancers: pheochromocytoma and paraganglioma. The approval for Azedra, a drug developed by Progenics Pharmacecuticals of Tarrytown, N.Y., was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. “This is a true breakthrough," said Dr. Daniel A. Pryma, an associate professor of radiology and radiation…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA (iobenguane I131).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Abstract Metaiodobenzylguanidine (MIBG) a guanithidine analogue, labelled with 123I and 131I, is used for imaging and therapy of neuroblastomas and various neural crest tumors like paragangliomas, pheochromocytomas, medullary cancer of thyroid and carcinoids since the past three to four decades. In this review article, we shall revisit MIBG as a radiopharmaceutical and its various applications in neural crest tumors. PMID: 30048149 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
Conditions:   Neuroendocrine Tumors;   Insulinoma;   Gastrinoma;   Glucagonoma;   Vipoma;   Pheochromocytoma;   Paraganglioma;   Neuroblastoma;   Ganglioneuroma;   Medullary Carcinoma;   Pituitary Adenoma;   Medulloblastoma;   Merkel Cell Carcinoma;   Small-cell Lung Cancer;   Meningioma;   Carcinoid Interventions:   Diagnostic Test: 68Ga-DOTATOC PET/CT;   Diagnostic Test: 18F-FDG PET/CT Sponsor:   British Columbia Cancer Agency Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractThe autonomic nervous system (ANS) is the main homeostatic regulatory system of the body. However, this widely distributed neural network can be easily affected by cancer and by the adverse events induced by cancer treatments. In this review, we have classified the ANS complications of cancer into two categories. The first includes direct cancer-related complications, such as primary ANS tumors (pheochromocytoma, paraganglioma or neuroblastoma), as well as autonomic manifestations induced by non-primary ANS tumors (primary brain tumors and metastases). The second comprises indirect ANS complications, which include ...
Source: Clinical Autonomic Research - Category: Research Source Type: research
Abstract There has been increasing evidence that pseudohypoxia—a phenomenon that we refer to as “gasping for air”––along with mitochondrial enzyme dysregulation play a crucial role in tumorigenesis, particularly in several hereditary pheochromocytomas (PHEOs) and paragangliomas (PGLs). Alterations in key tricarboxylic acids (TCA) cycle enzymes (SDH, FH, MDH2) have been shown to induce pseudohypoxia via activation of the hypoxia-inducible transcription factor (HIF) signaling pathway that is involved in tumorigenesis, invasiveness, and metastatic spread, including an association with re...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Paraganglioma | Pheochromocytoma